

Press Release

Symbiosis Pharmaceuticals Private Limited (SPPL)

May 12, 2017

Rating Assigned

Total Bank Facilities Rated*	Rs.24.75 Cr
Long Term Rating	SMERA BB+/Stable (Assigned)
Short Term Rating	SMERA A4+ (Assigned)

*Refer Annexure for details

Rating Rationale

SMERA has assigned the long-term rating of '**SMERA BB+**' (read as SMERA double B plus) and short term rating of '**SMERA A4+**' (read as SMERA A four plus) on the Rs.24.75 crore bank facilities of Symbiosis Pharmaceuticals Private Limited (SPPL). The outlook is '**Stable**'.

Symbiosis Pharmaceuticals Private Limited (SPPL) was incorporated in the year 2003 by Mr. V.D Gupta and Mr. Jagbir Singh. The company is engaged in the manufacturer of allopathic medicines in various forms like Soft gelatine, tablets, tubes, drops, Liquid Syrup, Ointment and Injectable etc. The company's manufacturing unit is located in Kala Amb, Himachal Pradesh. The company import raw material from China and also purchases material from the domestic market. The final products are sold in India as well as exported to countries like Afghanistan, Sri Lanka, Iraq and Nigeria.

Analytical approach: SMERA has combined the business and financial risk profiles of Symbiosis Pharmaceuticals Private Limited (SPPL) and Saitech Medicare Private Limited (SMPL). Both the entities, together referred to as the Symbiosis Group, are engaged in the same line of business, are under the same management, and have financial linkages. The main promoters of S. S. Group are Mr. V.D Gupta and Mr. Jagbir Singh.

List of key rating drivers and their detailed description

Strengths:

Long track record of operations and experienced management: The promoters, Mr. V.D Gupta and Mr. Jagbir Singh, have more than two decades of experience in the said line of business. Such a long experience has helped him in developing good relations with its customers and suppliers.

Healthy financial risk profile: Symbiosis Group has healthy financial risk profile marked by healthy interest coverage, moderate gearing, debt service coverage and networth. The interest coverage ratio has improved and stood at 2.27 times in FY2015-16 as compared to 2.18 times FY2014-15. Moreover, the gearing of the group is moderate and stands at 1.03 times in FY15-16 against 1.15 times in FY14-15. The networth of the group has improved and stood at Rs.29.70 crore in FY15-16 against Rs.26.88 crore in previous, owing to retention of profits in the business, which has transformed into improvement in capital structure. The net cash accrual (NCA)/total debt (TD) stood at 0.17 times in FY15-16 against the same in the previous year.

Reputed clientele: The Symbiosis Group has healthy relation with its clients like Alchemist Limited, A.N. Pharmacia Labs Pvt. Ltd., Bestochem Formulations India Ltd, Cipla Limited, D. R. John Lab Healthcare Pvt. Ltd., Indoco Remedies Limited, Morepen Laboratories Limited among others which has helped the company in steady increase in its revenues over the years. The company's revenue has increased to Rs.191.37 crore in FY15-16 against Rs.172.22 crore in F14-15. Further, the group has achieved the revenue of ~Rs. 210.00 crore in FY16-17.

Weaknesses:

Stretched Working capital cycle: The Symbiosis Group has stretched working capital cycle with high gross current assets (GCA) days of 216 days in FY15-16, which are increased from 209 days in FY14-15. The increase in GCA days is eminent from debtor days from 126 days in FY14-15 to same at 126 days in FY15-16. Inventory days stood at 68 days in FY14-15 to 61 days in FY15-16.

Intense competition: The Symbiosis Group faces intense competition from various players in India and overseas which is likely to impact operating performance and profitability.

Applicable Criteria

- Manufacturing Entities - <https://www.smera.in/criteria-manufacturing.htm>
- Application of Financial Ratios and Adjustments: <https://www.smera.in/criteria-fin-ratios.htm>
- Default Recognition: <https://www.smera.in/criteria-default.htm>
- Consolidation: <https://www.smera.in/criteria-consolidation.htm>

Outlook: Stable

SMERA believes that Symbiosis Group will continue to maintain a stable outlook over the medium term of improvement in operation and benefit from its experienced management. The outlook may be revised to 'Positive' if the company registers substantial growth in revenues and profitability while maintaining its debt protection metrics. Conversely, the outlook may be revised to 'Negative' in case of deterioration in the financial risk profile or working capital management.

About the Rated Entity

Symbiosis Pharmaceuticals Private Limited (SPPL) was incorporated in the year 2008 by Mr. V.D Gupta and Mr. Jagbir Singh. The company is engaged in the manufacture of allopathic medicines in various forms like soft gelatine, tablets, tubes, drops, liquid syrup, ointment and injectable etc. The company's manufacturing unit is located at Kala Amb, Himachal Pradesh. The Symbiosis Group import raw material from China and also purchases material from the domestic market. The final products are sold in India as well as exported to countries like Afghanistan, Sri Lanka, Iraq and Nigeria.

For FY2015-16, the company reported profit after tax (PAT) of Rs.1.63 crore on operating income of Rs.118.34 crore, as compared with PAT of Rs.1.63 crore on operating income of Rs.106.11 crore in FY2014-15. The net worth stood at Rs.19.48 crore as on 31 March, 2016 against Rs.17.85 crore a year earlier.

About the Group

Symbiosis Group was incorporated in the year 2003 by Mr. V.D Gupta and Mr. Jagbir Singh. The group is involved in the manufacturing of allopathic medicines in various forms like Soft gelatine, tablets, tubes, drops, Liquid Syrup, Ointment and Injectable etc. The group is situated at Kala Amb, Himanchal Pradesh.

Status of non-cooperation with previous CRA (if applicable): Not Applicable

Any other information: Not Applicable

Rating History for the last three years:

Name of Instrument /Facilities	FY 2018			FY 2017		FY 2016		FY 2015	
	Scale	Amt. (Rs. Crore)	Rating with Outlook	Date	Rating	Date	Rating	Date	Rating
Cash Credit	LT	18.75	SMERA BB+/Stable (Assigned)	-	-	-	-	-	-
Term Loan	LT	1.95	SMERA BB+/Stable (Assigned)	-	-	-	-	-	-
Letter of Credit	ST	3.50	SMERA A4+ (Assigned)	-	-	-	-	-	-
Bank Guarantee	ST	0.55	SMERA A4+ (Assigned)	-	-	-	-	-	-

*Annexure – Details of instruments rated:

Name of the Facilities	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. Crore)	Ratings/ Outlook
Cash Credit	N.A	N.A	N.A	18.75	SMERA BB+/Stable (Assigned)
Term Loan	N.A	N.A	N.A	1.95	SMERA BB+/Stable (Assigned)
Letter of Credit	N.A	N.A	N.A	3.50	SMERA A4+ (Assigned)
Bank Guarantee	N.A	N.A	N.A	0.55	SMERA A4+ (Assigned)

Note on complexity levels of the rated instrument:

<https://www.smerra.in/criteria-complexity-levels.htm>

Contacts:

Analytical	Rating Desk
Vinayak Nayak, Head – Operations, SMERA Bond Ratings Tel: 022-67141190 Email: vinayak.nayak@smerra.in	Varsha Bist Sr. Executive Tel: 022-67141160 Email: varsha.bist@smerra.in
Pradeep Bharti, Rating Analyst, Tel: 011-49731301 Email: pradeep.bharti@smerra.in	

ABOUT SMERA

SMERA Ratings Limited is a joint initiative of SIDBI, Dun & Bradstreet Information Services India Private Limited (D&B) and leading public and private sector banks in India. SMERA is registered with SEBI as a Credit Rating Agency and accredited by Reserve Bank of India. For more details, please visit www.smerra.in.

Disclaimer: A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.smerra.in) for the latest information on any instrument rated by SMERA.